Integration of Large-Scale Chromatography with Nanofiltration for an Ovine Polyclonal Product - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Integration of Large-Scale Chromatography with Nanofiltration for an Ovine Polyclonal Product
The authors examine the challenges of integrating a large-scale chromatography and nanofiltration process for purification of a polyclonal antibody.


Pharmaceutical Technology
Volume 33, Issue 1, pp. 62-70

Screening studies

The technical challenge in combining the SP chromatography step with the 20-nm nanofiltration step comes from matching flow requirements and pressure capabilities of the chromatography process with the flow and capacity requirements of the nanofiltration technology. At the same time, the nanofiltration technology must be used at ultra-large scale because the batch volumes of product at this stage reach 10,000 L. Flow and capacity capabilities of 20-nm nanofiltration technologies currently available vary significantly because of the use of different membrane types and pore geometries, or different filtration modes (dead end versus tangential flow).

Therefore, initial screening studies were undertaken to select the most appropriate 20-nm technology for this application. Nanofilters from three suppliers were used in the screening process; each meets the technical requirements for a large-scale disposable. The screening of these technologies was based on the following parameters:

  • Overall capacity in L/m2
  • Volumetric flow in L/m2/h
  • Virus reduction of PPV.

The screening study involved spiking a sample of the material to be nanofiltered with a preparation of PPV, at a virus concentration recommended by each supplier. Using a lab-scale nanofilter from each supplier, attempts were made to filter a volume equivalent to the required full-scale manufacturing volume of 400 L/m2.


Table I: Results of PPV screening studies at Catalent Pharma Solutions.
Table I outlines data from the non-GLP screening study conducted at Catalent Pharma Solutions (formerly Cardinal Health).

For filter B, a volume of 250 mL was obtained using a "run–spike–run" method in which only the last 50 mL was spiked. All other filtrate volumes were achieved using a "spike–run" method in which the full volume was spiked. The screening studies demonstrated that a 20-nm polyethersulphone (PESU)-based membrane (Sartorius Stedim Biotech, Aubagne, France) provided the best flowrate and capacity and met the virus clearance requirements. Once this nanofilter was selected, more detailed analysis of the virus clearance capability of the Sartorius virus-filter technology ("Virosart CPV") was initiated.

The first goal was to determine the capability of the filter to retain viruses throughout the filter lifetime. Because it was not feasible to spike the product with viruses at manufacturing scale, the filtration process had to be accurately scaled down to ensure that good laboratory practice (GLP) spiking studies were representative of the full-scale process.

The first phase of screening studies was carried out using bacteriophage PP7 as a model virus for small nonenveloped viruses. The PP7 bacteriophage assay has previously been described (4), and the use of PP7 as a model virus for mammalian viruses has been shown in previous studies (5, 6).


Table II: Results of PP7 spiking run.
The screening studies were performed using "Virosart CPV Minisart" filters at the Virology Department of Sartorius Stedim Biotech GmbH in Germany. Eight runs were performed, each using a 2.1 107/mL spike concentration of PP7 bacteriophage particles. All runs showed the same log reduction, and the results of a typical run are summarized in Table II.

The loading values are presented in Table II as L/m2 to reflect the volume to be filtered at manufacturing scale (maximum 400 L/m2 of filter area is required to meet the full batch volume). The results demonstrated that a good log reduction could be achieved throughout the filtration process, and this was replicated in all scaled-down PP7 runs.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here